Ann Med

1. GU T, Gunelli R, Chen T, Wang C, et al
   Robotic-assisted intracorporeal radical cystectomy with modified ileal conduit reduces ureteroileal anastomotic stenosis risk: a comparative study with laparoscopic surgery.
   Ann Med. 2026;58:2703361.
   

   >> Share

   
   

   
   Ann Surg Oncol

2. UGUR R, Demiriz B, Nisli O, Keskin ET, et al
   Who is at Risk of Residual Tumor and Pathologic Upstaging at a Second TURBT in Non-Muscle-Invasive Bladder Cancer?
   Ann Surg Oncol. 2026 Jul 27. doi: 10.1245/s10434-026-20268.
   

   >> Share

   
   

   
   Anticancer Res

3. KOBARI Y, Nakajima N, Saito A, Katsurayama N, et al
   Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
   Anticancer Res. 2026;46:4453-4460.
   

   >> Share

   
   

   
   Asia Pac J Oncol Nurs

4. WANG B, Zou J, Gao L, Lou F, et al
   Factors associated with help-seeking for urinary symptoms among Chinese patients with bladder cancer: A qualitative study.
   Asia Pac J Oncol Nurs. 2026;13:101001.
   

   >> Share

   
   

   
   Asian Pac J Cancer Prev

5. SALAH IBRAHIM A, Gamal DA, Hadia A, Hasaballah A, et al
   Superiority of Adjuvant Hyperfractionated Radiotherapy Over Chemotherapy Following Radical Cystectomy.
   Asian Pac J Cancer Prev. 2026;27:2571-2580.
   

   >> Share

   
   

   
   Biomed Pharmacother

6. DE MIGUEL-GARCIA G, Ruiz de Porras V, Font-Moron M, Font A, et al
   Urinary biomarkers in muscle-invasive bladder cancer: Current state and open opportunities for neoadjuvant chemotherapy response prediction and patient stratification.
   Biomed Pharmacother. 2026;202:119807.
   

   >> Share

   
   

   
   Biomedicines

7. PEREZ M, Lozano JJ, Ingelmo-Torres M, Domenech M, et al
   Correction: Perez et al. Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer. Biomedicines 2025, 13, 740.
   Biomedicines. 2026;14:1604.
   

   >> Share

   
   

   
   Biosens Bioelectron

8. GAO S, Jiang P, Liu X, Wang J, et al
   Cascaded confinement-encapsulated fluorescence nano-immunomachine for noninvasive urinary monitoring of bladder cancer.
   Biosens Bioelectron. 2026;312:119076.
   

   >> Share

   
   

   
   BJU Int

9. LISTER-WHELAN R, Senior E, Kendall J, Oughton JB, et al
   INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol.
   BJU Int. 2026 Jul 27. doi: 10.1111/bju.70387.
   

   >> Share

   
   

   
   Br J Cancer

10. ZHANG L, Liu Z, Ding Y, Sun J, et al
    Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.
    Br J Cancer. 2026;135:559-567.
    

    >> Share

    
    

    
    Br J Pharmacol

11. JIN J, Jin Y, Zhang R, Li Y, et al
    A novel quinoline and manganese-based carbon monoxide-releasing molecule for intravesical therapy of bladder cancer.
    Br J Pharmacol. 2026 Jul 30. doi: 10.1111/bph.70614.
    

    >> Share

    
    

    
    Can Urol Assoc J

12. HENDRI AZ, Robert R, Febriyanto T, Liliana B, et al
    Prognostic significance of TOP2A expression in bladder cancer: Systematic review and meta-analysis.
    Can Urol Assoc J. 2026 Jul 20. doi: 10.5489/cuaj.9572.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

13. ZHONG C, Masters M, Donzella SM, Bliwise DL, et al
    Risk of bladder cancer among male participants reporting nocturia in the Cancer Prevention Study-II.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    

    
    Cancer Treat Res Commun

14. BOGALE DE
    Activation of the PI3K/AKT/mTOR signaling pathway in bladder cancer pathogenesis and its therapeutic significance.
    Cancer Treat Res Commun. 2026;48:101340.
    

    >> Share

    
    

    
    Cancers (Basel)

15. MUKHERJEE N, Ji N, Hassouneh Z, Furman J, et al
    Unveiling the Paradoxical Tumor-Suppressive Role of CCL2/CCR2 in Bladder Cancer: A Novel Immunotherapeutic Strategy.
    Cancers (Basel). 2026;18:2267.
    

    >> Share

    
    
16. SALA-GONZALEZ N, Chekhun S, Fina C, Vilaseca M, et al
    Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review.
    Cancers (Basel). 2026;18:2269.
    

    >> Share

    
    
17. CANCERS EDITORIAL OFFICE
    Expression of Concern: Park et al. Isorhamnetin Induces Cell Cycle Arrest and Apoptosis Via Reactive Oxygen Species-Mediated AMP-Activated Protein Kinase Signaling Pathway Activation in Human Bladder Cancer Cells. Cancers 2019, 11, 1494.
    Cancers (Basel). 2026;18:2357.
    

    >> Share

    
    

    
    Cell Biol Int

18. SAYED U, Basheer NM, H M, Nayak PP, et al
    Kinesins in Bladder Cancer: Integrating Molecular Mechanisms and Treatment Approaches.
    Cell Biol Int. 2026;50:e70191.
    

    >> Share

    
    

    
    Clin Genitourin Cancer

19. AKPINAR C, Aydog E, Sahin B, Gulsen M, et al
    Contemporary Trends in the Surgical and Systemic Management of Muscle-Invasive Bladder Cancer: Insights From a Nationwide Multicenter Cohort in Turkey Over 2 Decades.
    Clin Genitourin Cancer. 2026;24:102612.
    

    >> Share

    
    
20. USUI K, Ito H, Muraoka K, Noto N, et al
    Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Variant Histology Bladder Cancer: A Multi-institutional Propensity Score-Matched Analysis.
    Clin Genitourin Cancer. 2026;24:102618.
    

    >> Share

    
    

    
    Clin Oncol (R Coll Radiol)

21. SUARTZ CV, Huber IMT, Brito PHS, de Lima RD, et al
    Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Neoadjuvant and Adjuvant Strategies.
    Clin Oncol (R Coll Radiol). 2026;57:104281.
    

    >> Share

    
    

    
    Comput Struct Biotechnol J

22. WANG YD, Lai YL, Liu CH, Su YT, et al
    Epigenomics-Guided Multi-Omics Integration Uncovers a Lipid-Metabolic Signature with Translational Utility in Bladder Cancer.
    Comput Struct Biotechnol J. 2026;35:0139.
    

    >> Share

    
    

    
    Curr Issues Mol Biol

23. GIMALOVA G, Gilyazova I, Khusnutdinova E, Pavlov V, et al
    SnoRNA and SNHG in Bladder Cancer: Molecular Mechanisms and Clinical Significance.
    Curr Issues Mol Biol. 2026;48:662.
    

    >> Share

    
    

    
    Curr Med Imaging

24. ZHU Y, Hu Q, Zhang R, Zhang G, et al
    Advancements in Endoscopic Optical Coherence Tomography for Urothelial Carcinoma: Research Progress and Clinical Applications.
    Curr Med Imaging. 2026;22:e15734056434411.
    

    >> Share

    
    

    
    ESMO Real World Data Digit Oncol

25. LAINEZ N, Martinez-Kareaga M, Sagastibeltza-Marinalarena N, Sanchez M, et al
    Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study.
    ESMO Real World Data Digit Oncol. 2026;13:100732.
    

    >> Share

    
    

    
    Eur Urol

26. GALSKY MD, Necchi A
    Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy.
    Eur Urol. 2026 Jul 27:S0302-2838(26)02271-2. doi: 10.1016/j.eururo.2026.
    

    >> Share

    
    

    
    Eur Urol Focus

27. DIANA P, Paciotti M, Frego N, Gallioli A, et al
    Intraoperative Skills for Transurethral Resection of Bladder Tumor: Objective Assessment and Construct Validity of the ENTRY Metrics.
    Eur Urol Focus. 2026;12:377-382.
    

    >> Share

    
    
28. ANTONELLI L, Afferi L, Del Giudice F, Bologna E, et al
    Discordant Response in Pelvic Lymph Nodes and Cystectomy Specimens After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2026 Jul 28:S2405-4569(26)00155.
    

    >> Share

    
    
29. OGUNKEYE J, Shkolyar E, Mach KE, Prendiville S, et al
    Performance of Urine Tumor DNA Detection in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Repeat Transurethral Resection.
    Eur Urol Focus. 2026 Jul 31:S2405-4569(26)00097.
    

    >> Share

    
    

    
    Front Cell Dev Biol

30. LUO Y, Liu X, Zhu S, Lin P, et al
    Clonal evolution and stromal crosstalk drive an invasive epithelial program in bladder cancer.
    Front Cell Dev Biol. 2026;14:1809774.
    

    >> Share

    
    

    
    Future Oncol

31. BEDKE J, Eccleston A, Unsworth M, Brinkmann J, et al
    Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan.
    Future Oncol. 2026 Jul 27:1-14. doi: 10.1080/14796694.2026.2696928.
    

    >> Share

    
    

    
    Gene

32. VERMA GK, Saini D, Chaudhary PK, Saha S, et al
    Association between heavy metal exposure and epigenetic modifications in patients with urinary bladder cancer.
    Gene. 2026 Jul 30:150330. doi: 10.1016/j.gene.2026.150330.
    

    >> Share

    
    

    
    Hum Pathol

33. CHEVILLE JC, Tekin B, Orme JJ, Jimenez RE, et al
    ERBB2 Copy Number Alterations and Protein Expression in Bladder Cancer Treated by Cystectomy.
    Hum Pathol. 2026 Jul 30:106217. doi: 10.1016/j.humpath.2026.106217.
    

    >> Share

    
    

    
    Immunotherapy

34. ISHIGAMI Y, Takahashi M, Nakatsukasa H, Shibano M, et al
    Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective study.
    Immunotherapy. 2026;18.
    

    >> Share

    
    

    
    Int J Biol Macromol

35. MO Z, Gai S, Qin X, Meng D, et al
    Retraction notice to "Correlation between TCF7 and bladder cancer and feasibility of Erlotinib targeting in bladder cancer: Molecular mechanism and expression of TCF7 recombinant protein" [Int. J. Biol. Macromol. 301 (2025) 140438].
    Int J Biol Macromol. 2026 Jul 30:153654. doi: 10.1016/j.ijbiomac.2026.153654.
    

    >> Share

    
    

    
    Int J Urol

36. KIKUCHI E, Tokumaru J, Kawai D, Ide R, et al
    Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study.
    Int J Urol. 2026;33:e70565.
    

    >> Share

    
    
37. MATSUSHITA Y, Kita Y, Mukai S, Joraku A, et al
    Oncological Outcomes and Prognostic Factors of Platinum-Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum-Based Chemotherapy Alone: A Propensity Score-Matched Analysis in a Real-World Population.
    Int J Urol. 2026;33:e70584.
    

    >> Share

    
    

    
    Int Urol Nephrol

38. ZHANG B, Wang C, Yang S, Li X, et al
    A comparison of efficacy and prognosis between RC48 combined immunotherapy and gemcitabine-cisplatin combined immunotherapy in bladder-preserving multimodal therapy for muscle-invasive bladder cancer.
    Int Urol Nephrol. 2026 Jul 25. doi: 10.1007/s11255-026-05275.
    

    >> Share

    
    

    
    J Hazard Mater

39. ZHU A, Singh Z, Holt SK, Schade GR, et al
    Impact of low levels of arsenic in drinking water with incident urologic cancers in Washington state.
    J Hazard Mater. 2026;514:142671.
    

    >> Share

    
    
40. CAO S, Chen Z, Wang S, Zhou Q, et al
    Arsenic induced deubiquitination modification of PLCE1 in a de-SUMO-dependent manner to affect malignant behavior in bladder epithelial cells.
    J Hazard Mater. 2026;514:142786.
    

    >> Share

    
    
41. TYAGI B, Tyagi A, Vashishta M, Tyagi N, et al
    Integrated analyses of the microbiome, metabolome, and spatial transcriptomics reveal sex-dependent bladder vulnerability to chronic inorganic arsenic.
    J Hazard Mater. 2026;514:142653.
    

    >> Share

    
    

    
    J Med Chem

42. WANG W, Li D, Liu J, Li L, et al
    Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors.
    J Med Chem. 2026 Jul 27. doi: 10.1021/acs.jmedchem.6c01714.
    

    >> Share

    
    

    
    J Toxicol Environ Health B Crit Rev

43. DA SILVA IM, Rocha LMO, de Andrade QG, de Lima LVA, et al
    Telomere stability pathway genes as predictors of susceptibility and prognosis in urothelial bladder cancer: review and bioinformatics analyses.
    J Toxicol Environ Health B Crit Rev. 2026.
    

    >> Share

    
    

    
    Lancet Oncol

44. TYSON MD 2ND, Nam JK, Joshi SS, Uchio EM, et al
    Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
    Lancet Oncol. 2026;27:983-993.
    

    >> Share

    
    

    
    Mol Biol Rep

45. ALI M, Soliman SE, Eldeeb TS, Aboeleuon E, et al
    Muscle invasion in bladder cancer is associated with increased expression of ATG5, LC3A and CHOP.
    Mol Biol Rep. 2026;53:1281.
    

    >> Share

    
    

    
    Mol Biomed

46. XU J, Xiong Y, Liu C, Sun J, et al
    Oncolytic virus OHSV2 induces pyroptosis in bladder cancer cells via the TLR4/NLRP3/Caspase-1/GSDMD pathway.
    Mol Biomed. 2026;7:119.
    

    >> Share

    
    

    
    Oncogene

47. GAO Y, Chen C, Sun R, Yao Y, et al
    LncRMRP drives bladder cancer invasion via a lactylation-driven positive feedback circuit.
    Oncogene. 2026 Jul 30. doi: 10.1038/s41388-026-03927.
    

    >> Share

    
    
48. ZHAN Y, Zhu C, Li Y, Wen C, et al
    Transcription factor EN1 governs a lipogenic USP18-ACLY axis to drive bladder cancer malignancy.
    Oncogene. 2026 Jul 28. doi: 10.1038/s41388-026-03910.
    

    >> Share

    
    
49. XIONG R, Wang M, Du J, Chai B, et al
    USP15-mediated deubiquitination of FIS1 impairs mitochondrial function and sensitizes bladder cancer cells to radiotherapy.
    Oncogene. 2026 Jul 27. doi: 10.1038/s41388-026-03918.
    

    >> Share

    
    

    
    Oncol Res

50. FREY LJ, Lache N, Fischer ND, Rolz N, et al
    Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder.
    Oncol Res. 2026;34:14.
    

    >> Share

    
    

    
    Pharmaceuticals (Basel)

51. LIU T, Li W, Yin Q, Liu D, et al
    Preclinical Models of Bladder Cancer: Barrier, Metabolic, and Translational Susceptibility.
    Pharmaceuticals (Basel). 2026;19:1116.
    

    >> Share

    
    

    
    Photodiagnosis Photodyn Ther

52. FUKUHARA H, Shigehisa R, Yamamoto S, Fukata S, et al
    Comparison of 5-aminolevulinic acid-induced hypotension of extending the oral administration period during photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer.
    Photodiagnosis Photodyn Ther. 2026 Jul 29:105591.
    

    >> Share

    
    

    
    Small

53. ZHANG Y, Shi X, Yuan Y, Gao X, et al
    MoN/Au/cTAT Boosted Sonochemotherapy Post-Intravesical Instillation in Bladder Cancer.
    Small. 2026 Jul 27:e11210. doi: 10.1002/smll.202511210.
    

    >> Share

    
    

    
    Support Care Cancer

54. TANAKA T, Oriyama T, Yamamoto T, Kimura S, et al
    Risk factors for chemotherapy-induced dysgeusia in patients receiving dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy: a retrospective observational study.
    Support Care Cancer. 2026;34:808.
    

    >> Share

    
    

    
    Urologie

55. NIEGISCH G, Grunewald C
    [Perioperative treatment of muscle-invasive bladder cancer : Current treatment concepts].
    Urologie. 2026 Jul 31. doi: 10.1007/s00120-026-02900.
    

    >> Share

    
    

    
    Wiad Lek

56. ABDULLAH OR, Short K, Alomari LHF, Ignatowicz A, et al
    Venous thromboembolism in urothelial bladder cancer - scope of the problem and patients' perspectives: VTE-UBC.
    Wiad Lek. 2026;79:1169-1178.
    

    >> Share

    
    

    
    World J Urol

57. GAN L, Wu J, Li Z, Cao H, et al
    Intra-corporeal robot-assisted versus open radical cystectomy: a meta-analysis.
    World J Urol. 2026;44:531.
    

    >> Share

    
    
58. HAGE L, Chakra MA, O'Donnell MA, Userovici M, et al
    Clinical patterns and pathogenesis of bladder leiomyoma: a multicenter observational study.
    World J Urol. 2026;44:526.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share